InvestorsHub Logo
Followers 31
Posts 6422
Boards Moderated 0
Alias Born 01/20/2016

Re: None

Monday, 04/01/2024 7:56:44 AM

Monday, April 01, 2024 7:56:44 AM

Post# of 461373
Posted by "Michael" on Anavex's Investor Forum-Facebook---good stuff !!! -------Dr. Daniel Klamer (?VP, Business Development? & Scientific Strategy / longtime, key member of the management team? at Anavex) will be presenting at the 15th Annual Outsourcing in Clinical Trials East Coast 2024 conference on May 21st:
CASE STUDY: TARGETING ALZHEIMER’S DISEASE AND DEMENTIA IN PARKINSON’S DISEASE WITH BLARCAMESINE (ANAVEX®2-73)
Clinical efficacy is associated with biomarker expression and restoration of neurodegenerative pathways
Blarcamesine (ANAVEX®2-73) treatment result in significant improvements in patients with Alzheimer’s Disease and in Parkinson’s Disease Dementia
Analysis demonstrates predictive biomarker of efficacy in Alzheimer’s Disease and in Parkinson’s Disease Dementia
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News